Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
SABESP Q1 2026 Earnings Call - EBITDA Surges 26% on Efficiency and Tariff Hikes, CapEx Accelerates to BRL 3.7B
SABESP delivered a robust first quarter in 2026, with adjusted EBITDA jumping 26% to BRL 3.8 billion as disciplined cost control and a January tariff adjustment drove margins to 63%. Revenue grew 11% ...
- Adjusted EBITDA surged 26% year-over-year to BRL 3.8 billion, with margins expanding to 62.9% driven by cost discipline and a January tariff hike.
- Adjusted net revenue grew 11% to BRL 6 billion, with price contributing 12% and volume up 2.4% despite a 4.6% drop in water production due to milder weather.
- CapEx accelerated 31% to BRL 3.7 billion in Q1, putting SABESP on track to meet its universalization targets ahead of schedule.
- +7 more takeaways
Oshkosh Corporation Q1 2026 Earnings Call - Fire Truck Delivery Delays Push Earnings Backward, But Backlog and Data Center Demand Keep Long-Term Targets Intact
Oshkosh reported Q1 2026 results that fell slightly short of expectations, with adjusted EPS of $0.85, largely due to fewer fire truck shipments held up by weather and travel disruptions. The company ...
- Oshkosh reported Q1 2026 adjusted EPS of $0.85, modestly below expectations, primarily due to fewer fire truck shipments in the Vocational segment.
- Consolidated sales were flat year-over-year at approximately $2.3 billion, with pricing and currency gains offsetting lower volume.
- The Access segment posted a strong book-to-bill ratio of 1.6, with orders exceeding $1.5 billion and a $1.8 billion backlog, driven by data center and mega-project demand.
- +7 more takeaways
AdvanSix Q1 2026 Earnings Call - Sulfur Costs Crush Margins, DEF Expansion Signals Strategic Pivot
AdvanSix navigated a brutal Q1 2026 where soaring sulfur and natural gas costs decimated adjusted EBITDA to just $5 million, despite 7% top-line growth. The company is leveraging its integrated ammoni...
- Adjusted EBITDA collapsed to $5 million, down $47 million year-over-year, primarily due to the absence of $26 million in prior-year insurance proceeds and a sharp spike in sulfur and natural gas input costs.
- Sales grew 7% year-over-year to $404 million, driven by 6% volume growth and 1% favorable pricing, but margin erosion from raw material inflation prevented top-line gains from translating to bottom-line strength.
- Sulfur prices hit record levels, settling at $655 per long ton in Q2 2026 with spot prices trading even higher, creating a 140% year-over-year surge that management expects to remain elevated for the foreseeable future.
- +7 more takeaways
Calumet, Inc. Q1 2026 Earnings Call - Strong Margins Offset by Shreveport Downtime as SAF Expansion Commences
Calumet, Inc. reported a transformative first quarter of 2026, navigating a volatile macro environment marked by geopolitical supply shocks and a pivotal EPA Renewable Volume Obligation (RVO) reset. W...
- Adjusted EBITDA came in at $50.1 million, down slightly from $55 million in Q1 2025, primarily due to a $30 million opportunity loss at the Shreveport refinery.
- The Shreveport unit suffered a loss of approximately 750,000 barrels of production due to organic chloride contamination, a serious risk that caused rapid steel erosion; the facility is now fully operational after swift corrective action.
- Specialties and Solutions (SPS) generated $44.3 million in Adjusted EBITDA, with margins temporarily compressed by crude spikes but protected by over 20 rapid price increases executed by the commercial team.
- +7 more takeaways
Olin Q1 2026 Earnings Call - Earnings Surge Driven by Supply Shocks and Cost Discipline
Olin reported a sharp sequential earnings improvement in Q1 2026, driven by structural cost reductions from the Beyond 250 program and a global chlor-alkali supply squeeze triggered by the Iran confli...
- Q1 2026 adjusted EBITDA came in at $86 million, with management guiding to $160 million-$200 million for Q2, signaling a massive sequential earnings jump driven by pricing and volume recovery.
- The Beyond 250 structural cost reduction program delivered $44 million in savings last year and is targeting an additional $100 million-$120 million in 2026, with $250 million cumulative savings by 2028.
- Global chlor-alkali supply is severely constrained, with 6%-9% of vinyls capacity offline due to the Iran conflict, forcing Asian producers into force majeure and tightening co-produced caustic soda availability.
- +7 more takeaways
Information Services Group Q1 2026 Earnings Call - AI Governance Becomes the New Growth Engine
ISG delivered a strong first quarter, with revenue reaching $61.2 million and adjusted EBITDA rising 12% to $8.3 million. The company’s AI transformation strategy is no longer theoretical. AI-related ...
- AI revenue is accelerating fast. AI-related revenue hit $21 million in Q1, up from $12 million a year ago, now making up roughly one-third of total firm-wide revenue.
- Margin expansion continues. Adjusted EBITDA grew 12% to $8.3 million, with margins expanding over 100 basis points to 13.5% for the sixth consecutive quarter of double-digit growth.
- Record-breaking governance deal. ISG signed its largest contract ever, a multi-year agreement valued up to $17 million to govern $300 million in tech spend for a top global manufacturer, spanning up to eight years.
- +7 more takeaways
Goldman Sachs BDC (GSBD) Q1 2026 Earnings Call - Legacy Portfolio Drag Masks Strong Modern Origination
Goldman Sachs BDC navigated a volatile first quarter by leaning into its transition from a legacy book to a modern, platform-backed origination engine. While reported metrics took a hit from mark-to-m...
- Legacy vs. Modern Split: The portfolio is now 58% post-integration originations and 42% legacy positions. The modern book is performing in line with expectations with minimal non-accruals, while the legacy book accounts for roughly 72% of quarterly losses and over 99.5% of non-accruals.
- Credit Quality Distinction: Management drew a strict line between mark-to-market volatility and true credit impairment. Unrealized losses are attributed to broader spread widening, not borrower solvency issues, whereas actual credit losses are concentrated in two idiosyncratic legacy names: One GI LLC and 3SI Security Systems Inc.
- Non-Accruals Rise to 4.7%: Total non-accruals increased from 2.8% to 4.7% of the portfolio at amortized cost, driven almost entirely by the two legacy names mentioned above. New vintage originations remain sound with negligible non-accruals.
- +7 more takeaways
FIS Q1 2026 Earnings Call - Margin Expansion and AI Orchestration Drive Record Cash Flow
FIS delivered a strong start to 2026, exceeding expectations across all key financial metrics while advancing its strategic pivot toward regulated AI orchestration. Pro forma revenue grew 6.5%, adjust...
- Pro forma revenue grew 6.5%, beating the high end of management's outlook, with Banking Solutions up 7.7% and Capital Markets up 2.9%.
- Adjusted EBITDA margins expanded 87 basis points year-over-year to 39.6%, driven by favorable product mix and disciplined cost optimization.
- Free cash flow surged 111% to $474 million, already representing 23% of the full-year $2.1 billion guide, with a long-term target of over $3 billion by 2028.
- +7 more takeaways
ALX Oncology Q1 2026 Earnings Call - Evorpacept and Zanidatamab Show Durable Responses in Heavily Pretreated HER2+ Breast Cancer
ALX Oncology reported strong Q1 2026 results, highlighted by new data from its ESMO Breast Cancer 2026 presentation on evorpacept combined with zanidatamab in heavily pretreated HER2-positive metastat...
- Evorpacept plus zanidatamab achieved a 33% ORR in heavily pretreated HER2-positive metastatic breast cancer patients (median 5 prior lines), with a median DOR of 20 months and median PFS of 3.6 months.
- In the subset of 10 centrally confirmed HER2-positive patients, the ORR rose to 60%, with a median DOR of 20.2 months and median PFS of 8.3 months.
- CD47 expression emerged as a strong predictive biomarker: all 5 patients with high CD47 expression (≥20%) responded to treatment, including 1 complete response, with a median PFS of 22 months versus 3.4 months in CD47-low patients.
- +7 more takeaways
Wendy's Q1 2026 Earnings Call - China Expansion and Project Fresh Turnaround
Wendy's Q1 2026 results reflect a company in the early stages of its Project Fresh turnaround. Global system-wide sales declined 5.5%, driven by a 7.8% drop in U.S. same-restaurant sales due to traffi...
- Global system-wide sales declined 5.5% in Q1 2026, with U.S. same-restaurant sales down 7.8% due to traffic declines, weather, and operational adjustments.
- International sales grew 6%, driven by unit growth in the Philippines and Mexico, and a historic agreement to open up to 1,000 restaurants in China over the next 10 years.
- U.S. company-operated restaurants, fully implementing Project Fresh operational initiatives, outperformed the broader system by 310 basis points, validating the turnaround playbook.
- +7 more takeaways